Rhythm Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Rhythm Pharmaceuticals reported third-quarter global net product sales of MCivri of $92.1 million, up 29 percent sequentially from $71.3 million in the second quarter.
- The U.S. generated $67.5 million, or 73 percent of product revenue, and U.S. acquired HO demand accounted for more than 90 percent of U.S. sequential revenue growth.
- The number of reimbursed patients on therapy globally increased by 20 percent during the third quarter.
- Since the March 19 launch, Rhythm received more than 700 patient start forms for acquired HO, including start forms for 71 clinical trial patients, and more than 500 prescribers had submitted start forms.
- As of the end of Q3, MCivri policies for acquired HO affected approximately 60% of Medicaid-covered lives and approximately 75% of commercial-covered lives; over 80% of approvals came within 60 days of receiving a start form.
- Rhythm launched MCivri for acquired HO in Japan on October 14th; its field teams had engaged 300 of 350 priority hospitals and identified more than 1,000 patients who may be eligible.
- In Europe, Rhythm submitted reimbursement dossiers in France, Italy, the United Kingdom, Spain, and the Netherlands, while the Germany GBA process was nearing completion.
- Rhythm ended the third quarter with approximately $321 million in cash, cash equivalents and short-term investments, and used approximately $3 million in cash from operations during the quarter.
- Third-quarter R&D expenses were $52.5 million, compared with $46 million in the same period last year; G&A expenses were $66.8 million, and GAAP EPS was a net loss of 61 cents per basic and diluted share.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised, and to withdraw your question, please press star 11 again. We ask that you please limit to one question. Please be advised that today's conference is being recorded. I would now like to turn the call over to Dave Connolly, Head of Investor Relations. Please go ahead. Thank you, Michelle.
I am Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the investor section of our website, ir.rhythmtx.com. Last night, we issued a press release announcing the amendment to our bivamelagon licensing agreement, and this morning, we issued our press release that provides our Q3 2026 financial results and a business update. Both press releases are available on our website. Our agenda is listed on slide 2. On the call today are David Meeker, our Chairman, Chief Executive Officer, and President, Jennifer Lee, Executive Vice President, Head of North America, Hunter Smith, Chief Financial Officer, and Yann Mazabraud, Executive Vice President, Head of International, is on the line joining us from Europe. On slide 3, I will remind you this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I will turn the call over to David Meeker, who will begin on slide 5.
Thank you, Dave. Good morning, and thank you for joining today. Rhythm continues to execute on multiple fronts, and we are excited to update you on our progress. Let us start on slide 5. We are very pleased to announce a strong third quarter, driven by an excellent start to the U.S. launch. Start forms are growing as expected, with encouraging market access translating to strong revenue performance of $92 million for the quarter. Jennifer will provide more details. We are excited about launching in Japan, with the first commercial patients already on treatment. We have every expectation that Japan will become our second-largest market. Yann will provide more color there. I will say more about our clinical development plans and the recently announced amendment to our LG Chem deal over the next couple slides. Slide 6 is a reminder of our three major strategic pillars.
The first pillar is the genetic indications, where we have multiple approvals, and we will be looking to expand the list of genes we are investigating. More to come on that in 2027. Second is HO, where we have a growing conviction in the magnitude of this opportunity globally, as you will hear more about today. Third is Prader-Willi syndrome, a devastating genetic disease with only one approved therapy in the U.S. and a desperate need for more treatment options. Let me spend a minute on why PWS is so strategically important to Rhythm and why we believe we can make a meaningful difference in this disease. I often draw the analogy to where the cystic fibrosis community was at the time the first disease-modifying treatments were being approved. Like CF, PWS patients are almost universally diagnosed at birth. The newborn is hypotonic, floppy, which leads to early genetic testing.
Average survival is age 30, which speaks to the severe unmet medical need, and providing care for these patients is challenging for their families, the healthcare system, and society as a whole. The PWS community is well-organized with a strong patient organization, specialized clinics staffed by experienced clinicians, providing these patients with greater access to the healthcare system than many patients with HO, for example, who still don't have a diagnosis. It is a complex genetic disease with multiple genes involved, but central to the disease is impaired signaling through the MC4R pathway. The six-month phase II data Dr. Miller presented at ENDO in June, showing a reduction in hyperphagia scores, anxiety scores, and BMI values, supports the potential role of an MC4R precision agonist in the management of this disease. Now, I will extend the CF analogy one step further.
Vertex recognized with their first approval in CF that they had a unique ability to make a major difference in this disease, so they literally doubled and tripled down on trying to optimize outcomes. Our strategy will be similar. We will run our first phase III trial with bivamelagon, but with the expectation, given the size and importance of this opportunity, we would develop both of our next-generation therapies in this disease. As previously indicated, the decision to start with bivamelagon has some practical aspects, most specifically related to CMC and availability of supply. We simply have an ability to start earlier than we would with RM-718. Furthermore, as with CF, we expect a monotherapy to work and be approved, but given the complexity of the disease, optimal outcomes will be achieved by combination therapies.
We are not prepared to discuss our portfolio at this time, we will do that in 2027, but the message today is simply that we are working to develop the best possible approach to MC4R diseases based on our understanding of the biology, and that will include proprietary combination approaches. Moving to slide seven, we're excited to initiate our phase III bivamelagon HO study. This is a 52-week comparably sized study to the original TRANSCEND study, with BMI as the primary endpoint. We hope to begin screening patients at the first sites by the end of the year and expect to dose the first patients in January. With a decision to proceed with bivamelagon in PWS, we will now engage with regulators with the goal of initiating a six-month phase III study in PWS with hyperphagia, as measured by HQ-CT, as a primary endpoint in 2027.
I want to provide a shout-out to the Rhythm teams who have not been idle on the development front. In preparation for the biva phase III studies, we needed to complete the following: a bioequivalence study with a new formulation, a food effect study, a drug-drug interaction study, and a hepatic impairment study, all of which have been completed satisfactorily in the past year, further de-risking bivamelagon as a core asset as we move into phase III trials. Finally, a brief word about our recently announced amendment of the LG Chem deal. Our decision to amend was driven by two factors. First, our growing belief in the overall opportunity related to MC4R pathway diseases, giving us the confidence to buy down the existing royalty.
Secondly, the original structure, despite our best efforts to align the two companies' interests, left us with an economic disincentive to fully develop bivamelagon, as that would drive a disproportionate royalty burden relative to developing RM-718, for example. In the current structure, we are fully aligned and can simply, as we would want to do, follow the science and develop the best possible treatment for the indication. I remind you that the patent protection for both bivamelagon and RM-718 extends into the 2040s, providing sustainable long-term value for shareholders. Hunter will provide more details on the LG transaction. I'll now turn the call over to Jen.
Thank you, David. I'll begin on slide 9. I'm pleased to report on the strong performance we're seeing in the U.S. launch of IMCIVREE for acquired hypothalamic obesity. In the third quarter, the second full quarter of launch, patient demand continues to be strong and consistent with what we experienced our first quarter of launch. We're seeing growth in a broadening base of prescribers. On the patient access side, reimbursement trends are highly encouraging, reflecting our ongoing payer engagement, leading to an increase in IMCIVREE policy adoption. On slide 10, I'll start with metrics related to patient demand. Since launch on March 19 and through the first two quarters, we have received more than 700 patient start forms for acquired HO, including start forms for 71 clinical trial patients.
Consistent with the first quarter, the patient age distribution remains evenly split amongst older and younger than 21, with 20% of patient start forms from patients between 4 and 12, pointing to the urgency that comes with caring for children. We are pleased with the distribution of time from hypothalamic injury among patients with prescriptions. Consistent with the prior quarter, approximately 15% of prescriptions have come from patients injured within the last two years. Hence, they were diagnosed and treated early in their disease journey. More than a third of patient start forms have come in for those whose hypothalamic injury was 10 years ago or more. These early dynamics are encouraging and demonstrate meaningful demand across a broad range of patients and a long-term growth opportunity in both incident and prevalent patients.
Slide 11 outlines how we are approaching the opportunity, balancing the institutional medical centers where patients begin their journey and then following the patients through their care. The first point of contact for patients with hypothalamic injury comes at a major medical center or large healthcare organization, where there is a concentration of new patients each year. Upon launch, we identified 43 of these priority accounts, and as we've had more engagement in the field, we continue to see a growth in the number of these identified accounts. Approximately 30% of patients remain engaged with the care teams at these larger centers, while approximately 70% of patients transition beyond their original point of care. The total number of accounts and percentage of patients within these accounts will continue to evolve throughout the launch.
With that said, our HCP tiering provided to our sales teams are based off of where the volume of potential patients are, and our commercial approach balances physician engagement at these institutional accounts, as well as the physicians across other care settings, reflecting where patients enter care and where they are receiving ongoing follow-up care. We remain focused on driving earlier diagnosis and treatment of acquired HO patients within a year of onset of their acquired hypothalamic obesity symptoms, while working to ensure prevalent patients who have been living with acquired HO for several years also get to an accurate diagnosis and treatment. Onto slide 12. We continue to see strong growth and a broadening base of prescribers. Launched to date, we have received start forms for more than 500 prescribers, including approximately 200 first-time acquired HO prescribers during the third quarter.
Of the HO prescribers to date, approximately 25% of them have written two or more IMCIVREE prescriptions for acquired HO, an incremental increase from the 20% repeat prescriber metric at the end of the second quarter. This points to a positive experience with prescribing IMCIVREE, but also reflects the early stage of the launch and the opportunity that remains, as many of these HCPs have more than one potential acquired HO patient under their care. Overall, 80% of prescribers are endocrinologists, evenly split between adult and pediatric endos, further supporting that acquired HO is a specialty opportunity. Slide 13. We've made significant progress with payers during the third quarter, and the early access trends and speed of approvals for reimbursement are highly encouraging. Payers are recognizing the differentiation and severity of acquired HO.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
20 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
